上海凱寶(300039.SZ)擬購買“保肺顆粒”新藥技術、臨牀試驗批件及其專利權
格隆匯2月28日丨上海凱寶(300039.SZ)公佈，公司(“甲方”)於近日擬使用自有資金購買“保肺顆粒”的新藥技術、臨牀試驗批件及其專利權。
“保肺顆粒”為河南中醫藥大學(“乙方”)開發的中藥6類新藥，該品種已於2018年7月獲得國家藥品監督管理局藥物臨牀試驗批件(No：2018L02751)，並取得專利(專利名稱：一種治療慢性阻塞性肺疾病肺脾氣虛的中藥，專利號：ZL201110205234.6)。
項目名稱：“保肺顆粒”臨牀試驗批件及其所涵蓋的新藥項目相關的所有專利及非專利技術及藥物臨牀試驗批件。
乙方將自行開發的、具有自主知識產權的“本項目”的轉讓給上海凱寶，向上海凱寶提供臨牀前研究及申報臨牀的全部研究資料及補充資料，提供生產工藝技術並指導生產3批符合穩定性試驗要求且質量合格的中試樣品以及臨牀試驗藥品的製備。乙方保證“保肺顆粒”臨牀前研究及臨牀研究的科學真實性，承擔合同中規定的權利、責任和義務。上海凱寶按照合同規定條款向乙方支付“保肺顆粒”項目的技術轉讓費，負責項目的臨牀研究、申報新藥證書、生產批文等工作及費用，並承擔合同中規定的權利、責任和義務。
該項目技術轉讓費、技術服務費和指導費，合計人民幣1290萬元,資金為公司自有資金。
“保肺顆粒”與公司儲備新藥的戰略研發方向是一致的，有利於公司解決產品較為單一的困擾，有利於豐富公司產品線，為公司在呼吸領域的深度發展奠定基礎，本項目產品上市後，可以為公司業績提供新的增長點，提升公司核心競爭力和可持續發展能力。
公司目前的主打產品痰熱清注射液多年來已形成的營銷網絡、營銷模式等有利於搭載“保肺顆粒”品種，進而有利於發揮公司營銷網絡的效率，有利於進一步形成市場規模。
公司擁有“保肺顆粒”品種的專利，有利於公司綜合運用法律手段、行政手段加以保護，有利於合理規劃和建設知識產權保護體系，有利於持續保持市場的獨佔性。
為豐富公司產品儲備，增強公司持續盈利能力，促進公司長遠發展，經過多方考察研究論證，公司決定購買該項目的全部技術和藥物臨牀試驗批件。“保肺顆粒”目前尚未啟動Ⅱ期臨牀研究，暫時不會對公司經營業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
